GR00057-A-1 | 106821730 | NM_020168 | PAK6 | M-004338-02 | 0.89 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 106821730 | NM_020168 | PAK6 | M-004338-02 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00121-A | 106821730 | | PAK6 | TRCN0000001748 | 20.23 | none | | | hit in RCC4 screen | Combinatorial effect with Von Hippel-Lindau (VHL) | Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. | Bommi-Reddy et al. | 2008 | 18948595 | Cell line | 786-O | Viability | Colorimetric | lentiviral library | Kinases | shRNA | Differential loss of viability (%) | > | Additional screen in RCC4 cells available | GR00184-A-1 | 106821730 | NM_020168 | PAK6 | M-004338-02 | -0.861881259877324 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00197-A-1 | 106821730 | 56924 | PAK6 | M-004338-02 | -0.959762928 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00221-A-1 | 106821730 | | PAK6 | TRCN0000001751 | -0.65 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 106821730 | | PAK6 | TRCN0000001750 | 0.15 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 106821730 | | PAK6 | TRCN0000001747 | 0.77 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 106821730 | | PAK6 | TRCN0000001748 | 0.82 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 106821730 | | PAK6 | TRCN0000001747 | -0.18 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 106821730 | | PAK6 | TRCN0000001748 | 0.67 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 106821730 | | PAK6 | TRCN0000001751 | 0.78 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 106821730 | | PAK6 | TRCN0000001750 | 1.69 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 106821730 | | PAK6 | TRCN0000001750 | -0.85 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 106821730 | | PAK6 | TRCN0000001747 | -0.41 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 106821730 | | PAK6 | TRCN0000001751 | 0.69 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 106821730 | | PAK6 | TRCN0000001748 | -1.18 | Decreased viability | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 106821730 | | PAK6 | TRCN0000001747 | 0.9 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 106821730 | | PAK6 | TRCN0000001750 | 3.21 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00230-A-1 | 106821730 | NM_020168 | PAK6 | TRCN0000001747 | 4.08 | Increased cell viability after pRB stimulation | | yes | | pRB-induced cell cycle regulation (1) | A kinase shRNA screen links LATS2 and the pRB tumor suppressor. | Tschöp et al. | 2011 | 21498571 | Cell line | SaOS2-TR-pRB | Cell number and viability | Colorimetrics | Lentiviral shRNA library | Kinases | shRNA | SD from the trendline | > 3.0 OR < -3.0 for > | | GR00230-A-1 | 106821730 | NM_020168 | PAK6 | TRCN0000001749 | np | none | | yes | Z-score >|3| for >= 2 shRNAs | pRB-induced cell cycle regulation (1) | A kinase shRNA screen links LATS2 and the pRB tumor suppressor. | Tschöp et al. | 2011 | 21498571 | Cell line | SaOS2-TR-pRB | Cell number and viability | Colorimetrics | Lentiviral shRNA library | Kinases | shRNA | SD from the trendline | > 3.0 OR < -3.0 for > | | GR00230-A-1 | 106821730 | NM_020168 | PAK6 | TRCN0000001750 | np | none | | yes | Z-score >|3| for >= 2 shRNAs | pRB-induced cell cycle regulation (1) | A kinase shRNA screen links LATS2 and the pRB tumor suppressor. | Tschöp et al. | 2011 | 21498571 | Cell line | SaOS2-TR-pRB | Cell number and viability | Colorimetrics | Lentiviral shRNA library | Kinases | shRNA | SD from the trendline | > 3.0 OR < -3.0 for > | | GR00231-A | 106821730 | NM_020168 | PAK6 | M-004338-02 | 1.604 | none | | yes | | Cell proliferation | Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. | Zhang et al. | 2011 | 21765947 | Cell line | HeLa | Viability | Electrical impedance | Human siARRAY - Protein Kinase and Cell Cycle libraries | Kinases and selected genes | siRNA | Z-score | < -1.96 OR > 1.96 | Additional information about cell titer blue cell viability screen | GR00236-A-1 | 106821730 | 56924 | PAK6 | M-004338-02 | 0.977775972516827 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00240-S-1 | 106821730 | NM_020168 | PAK6 | M-004338-02 | -0.24 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 106821730 | NM_020168 | PAK6 | M-004338-02 | 0.59 | none | | no | Z-score 0.435 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00249-S | 106821730 | 56924 | PAK6 | M-004338-02 | -1.23839 | none | | no | number of cells compared to control (%): 75.56 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 106821730 | 56924 | PAK6 | s32405 | 0.1501 | none | | no | number of cells compared to control (%): 92.69 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 106821730 | 56924 | PAK6 | s32406 | -1.58648 | Decreased viability | | no | number of cells compared to control (%): 45.70 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 106821730 | 56924 | PAK6 | s32407 | -2.49533 | Decreased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 50.48 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 106821730 | 701 | BUB1B | s260 | 0.46171 | none | | no | number of cells compared to control (%): 77.56 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00255-A-1 | 106821730 | 56924 | PAK6 | TRCN0000001747, TRCN0000001748, TRCN0000001749, TRCN0000001750, TRCN0000001751 | -0.518412712 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 106821730 | 56924 | PAK6 | TRCN0000001747, TRCN0000001748, TRCN0000001749, TRCN0000001750, TRCN0000001751 | 0.060591439 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 106821730 | 56924 | PAK6 | TRCN0000001747, TRCN0000001748, TRCN0000001749, TRCN0000001750, TRCN0000001751 | -0.355858689 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 106821730 | 56924 | PAK6 | TRCN0000001747, TRCN0000001748, TRCN0000001749, TRCN0000001750, TRCN0000001751 | 0.736438533 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 106821730 | 56924 | PAK6 | TRCN0000001747, TRCN0000001748, TRCN0000001749, TRCN0000001750, TRCN0000001751 | -0.174572524 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00300-A | 106821730 | | PAK6 | TRCN0000196369, TRCN0000001749, TRCN0000001748, TRCN0000001747, TRCN0000197072, TRCN0000195410, TRCN0000196314, TRCN0000199883, TRCN0000001750, TRCN0000001751 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00342-S-1 | 106821730 | | PAK6 | M-004338-02 | 1.4110864194562553 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (1) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 1 (MSC1a) | GR00342-S-2 | 106821730 | | PAK6 | M-004338-02 | 0.49340640999460095 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (2) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 2 (MSC1b) | GR00342-S-3 | 106821730 | | PAK6 | M-004338-02 | 0.3565020147723816 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (3) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 2, MSC preparation 1 (MSC2) | GR00343-S | 106821730 | 56924 | PAK6 | TRCN0000001747 | -0.14499999999999957 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 106821730 | 56924 | PAK6 | TRCN0000001749 | 0.1349999999999998 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 106821730 | 56924 | PAK6 | TRCN0000001748 | 0.34249999999999936 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 106821730 | 56924 | PAK6 | TRCN0000001751 | 0.03999999999999915 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 106821730 | 56924 | PAK6 | TRCN0000001750 | -1.6949999999999985 | shRNA abundance <= 50% | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data |